• Ultragenyx Pharmaceutical recently highlighted CEO Emil Kakkis’s participation in a fireside chat at Goldman Sachs’ 47th Annual Global Healthcare Conference and drew increased attention as one of hedge funds’ most promising mid-cap healthcare names, with analyst commentary emphasizing growing institutional interest in its rare-disease pipeline.
• A key focus of this attention is GTX-102 for Angelman syndrome, where analyst assessments and hedge fund interest underscore how expectations around upcoming Phase 3 ASPIRE results are shaping perceptions of the company’s future portfolio strength.
• We’ll now examine how rising institutional interest in GTX-102 for Angelman syndrome affects Ultragenyx’s existing investment narrative and risk-reward profile.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx today, you need to believe its rare-disease pipeline, led by gene therapies and GTX-102 for Angelman syndrome, can eventually support a sustainable, profitable business despite current losses and a history of regulatory setbacks. The recent bump in institutional interest and CEO visibility at Goldman Sachs reinforces attention on GTX-102, but it does not fundamentally change that the most important near term catalyst is the ASPIRE Phase 3 readout, while the biggest risk remains ongoing cash burn and potential dilution if profitability slips further out.

Against that backdrop, the most relevant recent development is the growing focus on GTX-102 after Cantor Fitzgerald raised its price target, citing institutional confidence in the Angelman program, while Wedbush highlighted the importance of ASPIRE Phase 3 data. This attention sits alongside other 2026 milestones such as FDA reviews for DTX401 and UX111, but for many investors the GTX-102 readout now feels like the clearest single event that could recalibrate sentiment across the entire Ultragenyx pipeline.

Yet investors should also be aware that if ASPIRE disappoints or timelines slip, the combination of high cash burn and limited cash runway could...

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $114.0 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.05 fair value, a 138% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts see Ultragenyx reaching about US$1.6 billion of revenue and US$312.9 million of earnings by 2029, a far more upbeat view than consensus and one that could be challenged or reinforced as the market reassesses GTX-102 and the company’s dependence on a small set of pivotal programs.

Explore 3 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.